IMPL Impel NeuroPharma, Inc

Impel NeuroPharma, Inc., a late-stage pharmaceutical company, focuses on the development and commercialization of therapies for patients suffering from central nervous system disease in the United States. Its lead product candidate is TRUDHESA, an upper nasal formulation of dihydroergotamine for the acute treatment of migraine. The company is also developing INP105, an upper nasal formulation of olanzapine for the acute treatment of agitation and aggression in autism spectrum disorder; and INP107, an upper nasal formulation of carbidopa/levodopa for the treatment of OFF episodes in Parkinson's disease. Impel NeuroPharma, Inc. was incorporated in 2008 and is headquartered in Seattle, Washington.

$8.82
As of 12/03/2021     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  04/23/2021
Outstanding shares:  23,039,393
Average volume:  231,715
Market cap:   $204,820,204
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    45258K109
ISIN:        US45258K1097
Sedol:      BMHR7K6
Valuation   (See tab for details)
PE ratio:   -8.12
PB ratio:   2.68
PS ratio:   0.00
Return on equity:   -53.83%
Net income %:   -44,888,784.62%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy